The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement

Journal Article · Mon Dec 05 04:00:00 EST 2016 · Alzheimer's & Dementia

DOI:https://doi.org/10.1016/j.jalz.2016.10.006· OSTI ID:1393230

Weiner, Michael W. ^[1]; Veitch, Dallas P. ^[2]; Aisen, Paul S. ^[3]; Beckett, Laurel A. ^[4]; Cairns, Nigel J. ^[5]; Green, Robert C. ^[6]; Harvey, Danielle ^[4]; Jack, Clifford R. ^[7]; Jagust, William ^[8]; Morris, John C. ^[3]; Petersen, Ronald C. ^[7]; Salazar, Jennifer ^[3]; Saykin, Andrew J. ^[9]; Shaw, Leslie M. ^[10]; Toga, Arthur W. ^[11]; Trojanowski, John Q. ^[12]

---

1. Dept. of Veterans Affairs Medical Center, San Francisco, CA (United States); Univ. of California, San Francisco, CA (United States)
2. Dept. of Veterans Affairs Medical Center, San Francisco, CA (United States)
3. Univ. of Southern California, San Diego, CA (United States)
4. Univ. of California, Davis, CA (United States)
5. Washington Univ. School of Medicine, St. Louis, MO (United States)
6. Brigham and Women's Hospital and Harvard Medical School, Boston, MA (United States)
7. Mayo Clinic, Rochester, MN (United States)
8. Univ. of California, Berkeley, CA (United States)
9. Indiana Univ. School of Medicine, Indianapolis, IN (United States)
10. Eli Lilly and Company, Indianapolis, IN (United States)
11. Univ. of Southern California, Los Angeles, CA (United States)
12. Univ. of Pennsylvania, Philadelphia, PA (United States)

Overall, the goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI-3, which began on August 1, 2016, is a 5-year renewal of the current ADNI-2 study. ADNI-3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Multimodal analyses will provide insight into AD pathophysiology and disease progression. Finally, ADNI-3 will aim to inform AD treatment trials and facilitate development of AD disease-modifying treatments.

• Research Organization: Univ. of California, Berkeley, CA (United States); Univ. of California, San Francisco, CA (United States)
• Sponsoring Organization: USDOE; National Inst. of Health (NIH) (United States)
• DOE Contract Number: AC02-05CH11231
• OSTI ID: 1393230
• Journal Information: Alzheimer's & Dementia, Journal Name: Alzheimer's & Dementia Journal Issue: 5 Vol. 13; ISSN 1552-5260
• Publisher: Elsevier
• Country of Publication: United States
• Language: English

Related Subjects

60 APPLIED LIFE SCIENCES
Alzheimer's disease
Amyloid phenotyping
Brain Health Registry
Centiloid method
Clinical trial biomarkers
Functional connectivity
Tau imaging